Screening for Safety-Relevant Off-Target Activities

Polypharmacology in Drug Discovery

Volumn , Issue , 2012, Pages 15-46

  Urban, Laszlo ^a   Whitebread, Steven ^a   Hamon, Jacques ^b   Mikhailov, Dmitri ^a   Azzaoui, Kamal ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Novartis Institute for BioMedical Research Basel   (Switzerland)

Author keywords

Drug discovery, in vitro safety, profiling; Pharmacology assays, interpretation of data; Safety related off target effects, screening

Indexed keywords

EID: 84859269730     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118098141.ch2     Document Type: Chapter

References (60)

1. Whitebread, S.; Hamon, J.; Bojanic, D.; Urban, L. (2005), In vitro safety pharmacology profiling: An essential tool for drug development, Drug Discov. Today 10, 1421-1433.
2. Cavero, I. (2009), Exploratory safety pharmacology: A new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations, Expert Opin. Drug Saf. 8, 627-647.
3. Chapman, T. M.; Goa, K L. (2003), Cilostazol: A review of its use in intermittent claudication, Am. J. Cardiovasc. Drugs 3, 117-138.
4. Robless, P.; Mikhailidis, D. P.; Stansby, G. P. (2008), Cilostazol for peripheral arterial disease, Cochrane Diabetes Syst. Rev. 23, 1-23.
5. Boswell-Smith, V.; Spina, D.; Page, C. P. (2006), Phosphodiesterase inhibitors, Br. J. Pharmacol. 147, S252-S257.
6. Paolini, G. V.; Shapland, R. H. B.; van Hoorn, W. P.; et al. (2006), Global mapping of pharmacological space, Nature Biotechnol. 24, 805-815.
7. Krejsa, C. M. et al. (2003), Predicting ADME properties and side effects: The BioPrint approach, Curr. Opin. Drug Discov. Dev. 6, 470-480.
8. McGivney,W. T.; Mullen, J. (2005), Cancer and managed care in the 21st century, Am. J. Manage. Care S509 (Suppl. 12/1)11-13.
9. Schechtman, K. B.; Gordon, M. E. (1994), The effect of poor compliance and treatment side-effects on sample size requirements in randomized clinical trials, J. Biopharm. Stat. 4, 223-232.
10. Kola, I.; Landis, J. (2004), Can the pharmaceutical industry reduce attrition rates? Nature Rev. 3, 711-715.
11. Azzaoui, K. J.; Faller, B.; Whitebread, S.; Jacoby, E.; Bender, A.; Jenkins, J.; Urban, L. (2007), Modeling promiscuity based on in vitro safety pharmacology profiling data, ChemMedChem 2, 874-880.
12. Urban, L.; Wang, J.; Bojanic, D.; Ward, S. Integrated approaches to lead optimization: Improving the therapeutic index, in Xu, J. J.; Urban, L., eds., Predictive Toxicology in Drug Safety Evaluation, Cambridge Univ. Press, 2010.
13. Faller, B.; Urban, L., Integrated risk assessment, in Faller, B.; Urban, L., eds., Hit and Lead Profiling, Wiley-VCH, Weinheim, 2009.
14. Netzer, R.; Bischoff, U.; Ebneth, A. (2003), HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery, Curr. Opin. Drug Discov. Dev. 6, 462-469.
15. Scheiber, J.; Jenkins, J.; Sukuru, S. C. K.; Bender, A.; Mikhailov, D.; Milik, M.; Azzaoui, K.; Whitebread, S.; Hamon, J.; Urban, L.; Glick, M.; Davies, J.W. (2009), Mapping adverse drug reactions in chemical space, J. Med. Chem. 52, 3103-3107.
16. Scheiber, J.; Chen, B.; Milik, M.; Sukuru, S. C. K.; Bender, A.;Mikhailov,D.; Whitebread, S.;Hamon, J.; Azzaoui, K.; Urban, L.; Glick, M.; Davies, J.; Jenkins, J. (2008), A comprehensive systems biology analysis gains insight into off-target mediated effects of drug candidates, J. Chem. Inform. Model. 49, 308-317.
17. Haas, H.; DeWitte, R. S.; Dunn-Dufault, R.; Stelzer, A. (2009), Process logistics, testing strategies and automation aspects, in Faller, B.; Urban, L., eds., Hit and Lead Profiling, Wiley-VCH, Weinheim, 2009.
18. Traebert, M.; Dumotier, B. (2005), Antimalarial drugs: QT prolongation and cardiac arrhythmias, Expert Opin. Drug Saf. 4, 421-431.
19. Paakkari, I. (2002), Cardiotoxicity of new antihistamines and cisapride, Toxicol. Lett. 127, 279-284.
20. Silvestre, J. S.; Prous, J. R. (2007), Comparative evaluation of hERG potassium channel blockade by antipsychotics, Methods Find. Exp. Clin. Pharmacol. 29(7): 457-465.
21. Wulff, H.; Castle, N. A.; Pardo, L. A. (2009), Voltage-gated potassium channels as therapeutic targets, Nature Rev. Drug Discov. 8, 982-1001.
22. Lowe, F. C. (2004), Role of the newer alpha-adrenergic-receptor antagonistsin [for] the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms, Clin. Ther. 26, 1701-1713.
23. Michelotti, G. A.; Price, D. T.; Schwinn, D. A. (2000), α1-Adrenergic receptor regulation: Basic science and clinical implications, Pharmacol. Ther. 88(3), 281-309.
24. Garraway, W. M.; Collins, G. N.; Lee, R. J. (1991), High prevalence ofbenign prostatic hypertrophy in the community, Lancet 338, 469-471.
25. Coffey, D. S. (1998), Controversies in the management of lower urinary tract symptoms: An overview, Br. J. Urol. 81, 1-5.
26. Lamb, J.; Crawford, E. D.; Peck, D.; et al. (2006), The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease, Science 313,1929-1935.
27. Hoyer, D.; Hannona, J. P.; Martin, G. R. (2002), Molecular, pharmacological and functional diversity of 5-HT receptors, Pharmacol. Biochem. Behav. 71, 533-554.
28. Lacivita, E.; Leopoldo, M.; Berardi, F.; Perrone, R. (2008), 5-HT1A receptor, an old target for new therapeutic agents, Curr. Top. Med. Chem. 8, 1024-1034.
29. Sun-Edelstein, C. et al. (2008), Drug-induced serotonin syndrome: A review, Expert Opin. Drug Saf. 7, 587-596.
30. Huang, X. P.; Setola, V.; Yadav, P. N. et al. (2009), Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment, Mol. Pharmacol. 76, 710-722.
31. Schade, R.; Andersohn, F.; Suissa, S.; Haverkamp, W.; Garbe, E. (2007), Dopamine agonists and the risk of cardiac-valve regurgitation, New Engl. J. Med. 356, 29-38.
32. Fayyaz, M.; Lackner, J. M. (2008), Serotonin receptor modulators in the treatment of irritable bowel syndrome, Ther. Clin. Risk Manage. 4, 41-48.
33. Bender, A.; Jenkins, J. L.; Glick, M.; Davies, J. W.; Azzaoui, K.; Hamon, J.; Fekete, A.; Urban, L.; Whitebread, S. (2007), Prediction of adverse drug reactions and off-target effects from chemical structure based on pharmacology data, ChemMedChem. 2, 1-15.
34. Goldstein, D. M. et al. (2008), High-throughput kinase profiling as a platform for drug discovery, Nature Rev. Drug Discov. 7, 391-397.
35. Nagy, I.; Santha, P.; Jancso, G.; Urban, L. (2004), The role of the vanilloid receptor (TRPV1) in physiology and pathology, Eur. J. Pharmacol. 500, 351-369.
36. Luo, X. J.; Lin, X.; Zhang, H.; et al. (2007), MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts, J. Biol. Chem. 282, 12363-12367.
37. Wang, J.; Urban, L.; Bojanic, D. (2007), Maximizing the use of in vitro ADMET tools to predict in vivo bioavailability and safety, Expert Opin. Drug Discov. 3, 641-665.
38. Faller, B.;Wang, J.; Zimmerlin, A.; et al. (2006), High-throughput in-vitro profiling assays: How useful for decision making? Expert Opin. Drug Metab. Toxicol. 2, 823-833.
39. Hamon, J.; Whitebread, S.; Techer-Etienne, V.; et al. (2009), Prospective in in vitro safety pharmacology profiling: What else beyond hERG? Future Med. Chem. 1, 1-21.
40. Pearce, B. C.; Sofia, M. J.; Good, A. C.; Drexler, D. M.; Stock, D. A. (2006), An empirical process for the design of high-throughput screening deck filters, J. Chem. Inform. Model. 46, 1060-1068.
41. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. (2004), Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia, Nature Rev. Drug Discov. 3, 353-359.
42. Hamon, J.; Azzaoui, K.; Whitebread, S.; et al. (2006), In vitro safety pharmacology profiling, Eur. Pharm. Rev. 1, 60-63.
43. Hughes, J. D.; Blagg, J.; Price, D. A.; et al. (2008), Physiochemical drug properties associated with in vivo toxicological outcomes, Bioorg. Med. Chem. Lett. 18, 4872-4875.
44. Leeson, P. D.; Springthorpe, B. (2007), The influence of drug-like concepts on decisionmaking in medicinal chemistry, Nature Rev. Drug Discov. 6, 881-890.
45. Peters, J.-U.; Schnider, P.; Mattei, P.; Kansy, M. (2009), Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds, ChemMedChem 4, 680-686.
46. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. (2002),Acommon mechanism underlying promiscuous inhibitors from virtual and high-throughput screening, J. Med. Chem. 45, 1712-1722.
47. Krejsa, C. M.; Horvath, D.; Rogalski, S. L.; Penzotti, J. E.; et al. (2003), Predicting ADME properties and side effects: The BioPrint approach, Curr. Opin. Drug Discov. Dev. 6, 470-480.
48. Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; et al. (2003), Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development, Cardiovasc. Res. 58, 32-45.
49. Mason, J. S.; Migeon, J.; Dupuis, P.; Otto-Bruc, A., Use of broad biological profiling as a relevant descriptor to describe and differentiate compounds: Structure-in vitro (pharmacology-ADME)-in Vivo (safety) relationships, in Vaz, R. J.; Klabunde, T., eds., Antitargets: Prediction and Prevention of Drug Side EffectsWiley-VCH,Weinheim, 2008, pp. 23-52.
50. Hamon, J.; Whitebread, S., In vitro safety pharmacology profiling: An important tool to decrease attrition, in Faller, B.; Urban, L., eds., Hit and Lead Profiling Wiley-VCH, Weinheim, 2009, pp. 273-295.
51. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; et al. (2008), A quantitative analysis of kinase inhibitor selectivity, Nature Biotechnol. 26 (1), 127-132.
52. Keiser,M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; et al. (2009), Predicting new molecular targets forknown drugs, Nature 462, 175-181.
53. Glick, M.; Davies, J. W.; Jenkins, J. L. (2006), Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases, J. Chem. Inform. Model. 46, 1124-1133.
54. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. (2007), Relating protein pharmacology by ligand chemistry, Nature Biotechnol. 25, 197-206.
55. Clark, M.;Wiseman, J. S. (2009), Fragment-based prediction of the clinical occurrence of long QT syndrome and torsade de pointes, J. Chem. Inform. Model. 49, 2617-2626.
56. Campillos, M.; Kuhn, M.; Gavin, A. C.; Jensen, L. J.; Bork, P. (2008), Drug target identification using side-effect similarity, Science 321, 263-266.
57. Keiser,M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; et al. (2009), Predicting new molecular targets for known drugs, Nature 462, 175-181.
58. Rihel, J.; Prober, D. A.; Arvanites, A.; Lam, K.; Zimmerman, S.; et al. (2010), Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation, Science 327, 348-351.
59. Kokel, D.; Bryan, J.; Laggner, C.; White, R.; Cheung, C.Y.; Mateus, R.; et al. (2010), Rapid behavior-based identification of neuroactive small molecules in the zebrafish, Nature Chem. Biol. 6, 231-237.
60. Jenkins, J.; Urban, L. (2010), A fishing net for catching neuroactive compounds, Nature Chem. Biol. (News & Views) 6, 172-173.